Drug intelligence / Profile preview

glucagon + insulin aspart

Development stage
Unknown
Lead developer
Novo Nordisk
Modality
Recombinant Proteins and Enzymes
Administration
Subcutaneous, Intramuscular, Intranasal
01

Overview

Glucagon and insulin aspart represent a therapeutic combination used in diabetes management. Insulin aspart is a fast-acting insulin analog that helps control blood glucose levels by promoting glucose absorption from the bloodstream. It has a single amino acid substitution at position B28 where proline is replaced with aspartic acid, which decreases its propensity to form hexamers and gives it a higher rate of absorption following subcutaneous administration compared to native insulin. Glucagon works in opposition to insulin, raising blood glucose levels when they fall too low. This combination is particularly important for managing hypoglycemia (low blood sugar) that can occur with insulin therapy. Patients using insulin aspart are often advised to have glucagon available as an emergency treatment for severe hypoglycemic episodes.

02

Targets

INSR (Insulin receptor)GCGR (Glucagon receptor)

Beyond the preview

Go deeper on glucagon + insulin aspart.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on glucagon + insulin aspart.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call